EP0199753A1 - Anticorps monoclonaux et leur utilisation - Google Patents

Anticorps monoclonaux et leur utilisation

Info

Publication number
EP0199753A1
EP0199753A1 EP19850905079 EP85905079A EP0199753A1 EP 0199753 A1 EP0199753 A1 EP 0199753A1 EP 19850905079 EP19850905079 EP 19850905079 EP 85905079 A EP85905079 A EP 85905079A EP 0199753 A1 EP0199753 A1 EP 0199753A1
Authority
EP
European Patent Office
Prior art keywords
treponema
antigen
antigens
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19850905079
Other languages
German (de)
English (en)
Inventor
Bruce William Wright
Peter John Cox
Alice Margaret Noyes
Danny Widdows
Clive Graham Copley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TECHNOLOGY LICENCE Co Ltd
Original Assignee
TECHNOLOGY LICENCE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TECHNOLOGY LICENCE Co Ltd filed Critical TECHNOLOGY LICENCE Co Ltd
Publication of EP0199753A1 publication Critical patent/EP0199753A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • monoclonal antibodies specific for the antigens or species of Treponema are desired which when, used will rapidly diagnose the presence of such organisms in specimens.
  • Treponema pallidum T. dentiu ⁇ i
  • T. micro- dentium T. perlegium
  • T. cuniculi T. refringens
  • T. macrodentium T. mucosum
  • Treponema will be described with particular reference to Treponema pallidum, as it is the best known species.
  • Treponema pallidum is the causative agent of syphilis.
  • Syphilis is a disease which declined in frequency with the introduction of penicillin, but has now stabi ⁇ lized in frequency and actually increased due to a more permissive society. The local and constitutional symptoms of the disease are often subtle and the diagnosis delayed. The regular use of serological tests weeks after exposure
  • a wide variety of isotopic and nonisotopic immunoassays have been utilized in conjunction with monoclonal antibodies to test for the pres ⁇ ence of an antigenic substance.
  • agglutination, i ⁇ ununo-fluorescent, chemilum ⁇ inescent or fluorescent immunoassay, immuno- electron microscopy, radiometric assay systems, radio immunoassays, and enzyme-linked immunoassays are the most common techniques used with the monoclonal antibodies. Other techniques include bioluminescent, fluorescence polarization, and photon-counting immunoassays.
  • EIA enzyme-linked immunoassay procedure
  • the enzyme-linked monoclonal antibody can then be used in the known enzyme-linked immunosor- bent assay procedure to determine the presence of an antigenic substance.
  • the serotype of the infecting organism can be determined, and appropriate treatment can then be initiated to rapidly and efficiently eliminate the disease.
  • the present invention provides novel mono ⁇ clonal antibodies for use in accurately and rapidly diagnosing samples for the presence of Treponema antigens and/or organisms.
  • the present invention com ⁇ prises monoclonal antibodies specific for an antigen or species of Treponema; in particular, the antigens or species of Treponema pallidum (designated as Treponema pallidum I, II, III, or IV), and the antigens or species of T. dentium, refringens, T. macrodentium, T. mucosum, as well as a monoclonal antibody broadly cross- reactive with an antigen for each species of the genus Treponema.
  • the antigens or species of Treponema pallidum designated as Treponema pallidum I, II, III, or IV
  • T. dentium, refringens, T. macrodentium, T. mucosum as well as a monoclonal antibody broadly cross- reactive with an antigen for each species of the genus Treponema.
  • the invention also comprises labeled mono ⁇ clonal antibodies for use in diagnosing the presence of the Treponema antigens, each com ⁇ prising a monoclonal antibody against one of the above-mentioned antigens to Treponema or to a particular species thereof and linked thereto an appropriate label.
  • the label can be chosen from the group consisting of a radioactive iso ⁇ tope, enzyme, fluorescent compound, chemilumines ⁇ cent compound, bioluminescent compound, ferromag ⁇ netic atom, or particle, or any other label.
  • the invention further comprises the process for diagnosing the presence of Treponema anti ⁇ gens or organisms in a specimen comprising con ⁇ tacting said specimen with the labeled monoclonal antibody in an appropriate immunoassay procedure.
  • the invention is also directed to a therapeutic composition
  • a therapeutic composition comprising a mono ⁇ clonal antibody for an antigen of Treponema and a carrier or diluent, as well as kits contain ⁇ ing at least one labeled monoclonal antibody o an an gen o a rep n .
  • the monoclonal antibodies of the present invention are prepared by fusing spleen cells, from a • mammal which has been immunized against the particular Treponema antigen, with an appro ⁇ priate myeloma cell line, preferably NSO (unclon- ed), P3NS1-Ag4/1, or Sp2/0 Agl4.
  • the resultant product is then cultured in a standard HAT (hy ⁇ poxanthine, aminopterin, and thymidine) medium. Screening tests for the specific monoclonal antibodies are employed utilizing immunoassay techniques which will be described below.
  • the immunized spleen cells may be derived from any mammal, such as primates, humans, rodents (i.e., mice, rats, and rabbits), bovine, ovine, canine, or the like, but the present invention will be described in connection with mice.
  • the mouse is first immunized by injection of the particular Treponema antigen chosen generally for a period of approximately eleven weeks. When the mouse shows sufficient antibody produc ⁇ tion against the antigen, as determined by conven ⁇ tional assay, it is given a booster injection of the appropriate Treponema antigen, and then killed so that the immunized spleen may be remov- . immunized spleen cells and an appropriate myeloma cell line.
  • the fused cells yielding an antibody which give • a positive response to the presence of the particular Treponema antigen are removed and cloned utilizing any of the standard methods.
  • the monoclonal antibodies from the clones are then tested against standard antigens to determine their specificity for the particular Treponema antigen.
  • the monoclonal antibody selected, which is specific for the particular Treponema antigen or species, is then bound to an appropri ⁇ ate label.
  • Amounts of antibody sufficient for labeling and subsequent commercial production are produced by the known techniques, such as by batch or continuous tissue culture or culture in vivo in mammals, such as mice.
  • the monoclonal antibodies may be labeled with a multitude of different labels, such as enzymes, fluorescent compounds, luminescent compounds, radioactive compounds, ferromagnetic labels, and the like.
  • labels such as enzymes, fluorescent compounds, luminescent compounds, radioactive compounds, ferromagnetic labels, and the like.
  • the present invention will be described with reference to the use of an enzyme labeled monoclonal antibody.
  • Some o e enzymes u ze a a ne phosphatase, glucose oxidase, galactosidase, peroxidase, or urease, and the like.
  • Such linkage with enzymes can be accomplished by .any one of the conventional and known methods, such as the Staphylococcal Protein A method, the glutaraldehyde method, the benzoquinone method, or the periodate method.
  • EIA enzyme- linked immunosorbent assay
  • Fluorescent-immunoassay is based on the labeling of antigen or antibody with fluorescent probes. A nonlabeled antigen and a specific antibody are combined with identical fluorescently antigen compete for antibody binding sites. The amount of labeled antigen bound to the antibody is dependent upon, and therefore a measurement • of, the concentration of nonlabeled antigen. Examples of this particular type of fluorescent- immunoassay would include heterogenous systems such as Enzyme-Linked Fluorescent Immunoassay, or homogeneous systems such as the Substrate Labeled Fluorescent Immunoassay. The most suit ⁇ able fluorescent probe, and the one most widely used is fluorescein. While fluorescein can be subject to considerable interference from scattering, sensitivity can be increased by the use of a fluorometer optimized for the probe utilized in the particular assay and in which the effect, of scattering can be minimized.
  • Fluorescence polarization In fluorescence polarization, a labeled sample is excited with polarized light and the degree of polarization of the emitted light is measured. As the antigen binds to the antibody its rotation slows down and the degree of polari ⁇ zation increases. Fluorescence polarization is simple, quick, and precise. However, at the present time its sensitivity is limited to the micromole per liter range and upper nano- mole per ter range w t respect to ant gens in biological samples.
  • Luminescence is the emission of light by an atom or molecule as an electron is transferred to the ground state from a higher energy state.
  • the free energy of a chemical reaction provides the energy required to produce an inter ⁇ mediate reaction or product in an electronically excited state. Subsequent decay back to the ground state is accompanied by emission of light.
  • Bioluminescence is the name given to a special form of chemiluminescence found in biological systems, in which a catalytic protein or enzyme, such as luciferase, increases the efficiency of the luminescent reaction. The best known chemiluminescent substance is luminol.
  • a further aspect of the present invention is a therapeutic composition
  • a therapeutic composition comprising one or more of the monoclonal antibodies to the particular Treponema antigen or species, as well as a pharmacologically acceptable carrier or diluent.
  • Such compositions can be used to treat humans and/or animals afflicted with some form of Treponema infections and they are used in amounts effective to cure; an amount which ual being treated and the severity of the infec ⁇ tion.
  • One or more of the monoclonal antibodies can be assembled into a diagnostic kit for use in diagnosing for the presence of an antigen, antigens, or species of Treponema in various specimens. It is also possible to use the broadly cross-reactive monoclonal antibody which can identify the genus Treponema alone or as part of a kit containing antibodies that can identify other bacterial genera or species of Treponema and/or other bacteria.
  • kits In the past there have been difficulties in developing rapid kits because of undesirable cross-reactions of specimens with antiserum.
  • the use of monoclonal antibodies can eliminate these problems and provide highly specific and rapid tests for diagnosis.
  • a rapid and precise kit could replace or augment existing tests and permit early direct therapy using precise antibiotics. Avoiding multiple antibiotics or more expensive or hazardous antibiotics would represent substantial patient and hospital sav ⁇ ings.
  • a kit can be used on an out-patient basis. At present the lack of a rapid test giving "same day" answers may delay the initiation of treatment until the patient has developed more severe symptoms or may require the initiation of more costly therapy in a sick patient. A test that would return results within an hour or two would be a substantial convenience to patients.
  • kit could be included as a component in a comprehensive line of compatible immunoassay reagents sold to reference laboratories to detect the species and serotypes of Treponema.
  • kits comprising at least one labeled monoclonal antibody against a particular Treponema antigen or species, as • well as any appropriate stains, counterstains, or reagents.
  • Specific antigens to be detected in this kit include the antigens of Treponema pallidum (applicant has further divided this species into four subgroups: Treponema pallidum I, II, III or IV), _ ⁇ dentiu , T. microdentium, T. permur, T. cuniculi, T. refringens, T. macrodentium and T_ ; _ mucosum.
  • Monoclonal diagnostics which detect the presence of Treponema antigens can also be used in periodic testing of water sources, food supplies and food processing operations.
  • the present invention describes the use of the labelled monoclonal antibodies to determine the presence of a standard antigen
  • the invention can have many applications in diagnosing the presence of antigens by determining whether specimens such as urine, blood, stool, water and milk contain the particular Treponema antigen. More particularly, the invention could be utilised as a public health and safety diagnostic aid, whereby specimens such as -water or food could be tested for possible contamination.
  • DMEM Dulbecco's Modified Eagles Medium
  • FCS Foetal Calf Serum
  • PBS phosphate-buffered saline
  • % T refers to vaccine concentration measured in a 1 cm light path
  • Monoclonal antibodies of the present invention are prepared generally according to the method of Koehler and Milstein, Eur. J. Immunol, j ⁇ , (1975) 292.
  • EXAMPLE 1 A. Animal Immunisation
  • mice are injected with prepared Treponema pallidum antigen obtained from the PHLS prepared as a 15% suspension in glycerine.
  • the mice are given intramuscular and/or intravenous injections (0.05 ml 80% T vaccine) of prepared vaccine, twice im (in CFA) with a 4 week interval, and twice iv (in PBS) afer further 2 and 4 week intervals.
  • the mice are bled approximately six days after the last injection and the serum tested for antibodies by assay.
  • a conventional assay used for this serum titer testing is the enzyme-linked immunosorbent assay system.
  • mice show antibody production after this regimen, generally a positive titer of at least 10,000, a mouse is selected as a fusion donor and given a booster injection (0.02 ml 80% T vaccine) intravenously, three days prior to splenectomy.
  • B. Cell Fusion Spleen cells from the immune mice are harvested three days after boosting, by conventional techniques. First, the donor mouse selected is killed and surface-sterilised by immersion in 70% ethyl alcohol. The spleen is then removed and immersed in approximately 2.5 ml DMEM to which has been added 3% FCS.
  • the spleen is then gently homogenised in a LUX homogenising tube until all cells have been released from the membrane, and the cells are washed in 5 ml 3% FCS-DMEM.
  • the cellular debris is then allowed to settle and the spleen cell suspension placed in a 10 ml centrifuge tube. The debris is then rewashed in 5 ml 3% FCS-DMEM. 50 ml suspension are then made in 3% FCS-DMEM.
  • the myeloma cell line used is NS0 (uncloned) , obtained from the MRC Laboratory of Molecular Biology in Cambridge, England.
  • the myeloma cells are in the log growth phase, and rapidly dividing.
  • Each cell line is washed using, as tissue culture medium, DMEM containing 3% FCS.
  • the spleen cells are then spun down at the same time that a relevant volume of myeloma cells are spun down (room temperature for 7 minutes at 600 g) , and each resultant pellet is then separately resuspended in 10 ml 3% FCS-DMEM.
  • 0.1 ml of the suspension is diluted to 1 ml and a haemacytometer with phase microscope is used.
  • 0.1 ml of the suspension is diluted to 1 ml with Methyl Violet-citric acid solution, and a haemacytometer and light microscope are used to count the stained nuclei of the cells.
  • x 10 8 Spleen cells are then mixed with 5 x 107 myeloma cells, the mixture washed in serum-free DMEM high in glucose, and centrifuged, and all the liquid removed.
  • the resultant cell pellet is placed in a 37°C water-bath.
  • each well contains 1.0 ml of the standard HAT medium (hypoxanthine, aminopterin and thymidine) and a feeder layer of Balb/c
  • the wells are kept undisturbed, and cultured at 37°C in 9% COfest air at approximately 100% humidity.
  • the wells are analysed for growth, utilising the conventional inverted microscope procedure, after about 5 to 10 days.
  • screening tests for the specific monoclonal antibody are made utilising the conventional enzyme immunoassay screening method described below.
  • the clones may be assayed by the enzyme immunoassay method to determine antibody production.
  • the monoclonal antibodies from the clones are screened by the standard techniques for binding to the antigen, prepared as in the immunisation, and for specificity in a test battery of the class bearing different antigens. Specifically, a grid of microtiter plates containing a representative selective of organisms is prepared, boiled, and utilised as a template to define the specificity of the parent group. The EIA immunoassay noted above may be used. Specificity to infected testes is observed.
  • the cells are then centrifuged at 1200 g for approximately 10 minutes, the cells discarded, and the antibody-rich ascites fluid collected.
  • the fluid is titrated, as noted above, to establish presence and level of antibody, and purified.
  • Purification is accomplished using the protein A - Sepharose method. More particularly, about 10 ml of the ascites fluid are filtered through glass wool and centrifuged at 30,000 g for 10 minutes. The ascites is then diluted with twice its own volume of cold phosphate buffer (0.1 M sodium phosphate, pH 8.2). The diluted ascites is loaded on to a 2 ml column of protein A - Sepharose which has previously been equilibrated with phosphate buffer. The column is washed with 40 ml phosphate buffer, and the monoclonal antibody is eluted with citrate buffer (0.1 M sodium citrate, pH 3.5) into sufficient IM tris buffer, pH 9.0, to raise the pH immediately to about 7.5. The eluate is dialysed in 2 x 1000 ml PBS at +4°C.
  • citrate buffer 0.1 M sodium citrate, pH 3.5
  • the suspension is stirred for a further 30 minutes.
  • the precipitate is then harvested by centrifugation at 10,000 g for 10 minutes.
  • the precipitate is dissolved in a minimum volume of either cold phosphate/EDTA buffer (20mM sodium phosphate, lO M EDTA, pH 7.5, + 0.02% sodium azide) for DEAE-cellulose chromatography, or phosphate buffer (O.lM sodium phosphate, pH 8.2 + 0.02% sodium azide) for protein A-Sepharose chromatography.
  • the dissolved precipitate is dialysed versus 2 x 1000 ml of the dissolution buffer at +4°C, and the appropriate chromatography step carried out as previously described.
  • the monoclonal antibody specific against the antigen, prepared as above, is linked to an enzyme, viz. highly-purified alkaline phosphatase.
  • the one-step glutaraldehyde method or benzoquinone conjugation is used.
  • 3 mg monoclonal antibody in about 1 ml of solution
  • 10 mg alkaline phosphatase Sigma Type VII-T
  • the volume is made up to 2.5 ml with PBS, and 25 ⁇ l of a 20% glutaraldehyde in PBS solution are added.
  • the conjugation mixture is left at room temperature for 1.5 hours. After this time, glutaraldehyde is removed by gel filtration on a Pharmacia PH-10 (Sephadex G-25 M) column, previously equilibrated in PBS.
  • the conjugate is eluted with 3.5 ml PBS and then dialysed against 2 x 2000 ml of TRIS buffer (50 mM TRIS, 1 mM magnesium chloride, pH 8.0, plus 0.02% sodium azide) at +4°C. To the dialysed conjugate is added 1/lOth its own volume of 10% BSA in TRIS buffer. The conjugate is then sterile-filtered through a 0.22 ⁇ m membrane filter into a sterile amber vial and stored at +4°C.
  • TRIS buffer 50 mM TRIS, 1 mM magnesium chloride, pH 8.0, plus 0.02% sodium azide
  • Example 3 The procedure of Example 1 may be repeated to prepare a monoclonal antibody against Reiters treponeme, obtained from PHLS as a spirilate broth.
  • EXAMPLE 3 The procedure of Example 1 may be repeated to prepare a monoclonal antibody against Reiters treponeme, obtained from PHLS as a spirilate broth.
  • Example 1 The general procedure of Example 1 may be followed to produce a monoclonal antibody broadly cross-reactive with an antigen of all species of the genus Treponema.
  • Tests using the present invention are superior to existing tests, based on the following advantages: (i) greater accuracy? (ii) same day results, within an hour or two; (iii) reduction in amount of skilled labour required to administer laboratory procedures, resulting in reduced labour costs; (iv) reduction in laboratory time and space used in connection with tests, resulting in reduced overhead expenses; and (v) improved therapy based upon early, precise diagnosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticorps monoclonaux du genre Treponema, anticorps marqués, compositions et kits les contenant, et leur utilisation dans le diagnostic de l'antigène et le traitement.
EP19850905079 1984-10-19 1985-10-16 Anticorps monoclonaux et leur utilisation Withdrawn EP0199753A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848426465A GB8426465D0 (en) 1984-10-19 1984-10-19 Monoclonal antibodies
GB8426465 1984-10-19

Publications (1)

Publication Number Publication Date
EP0199753A1 true EP0199753A1 (fr) 1986-11-05

Family

ID=10568434

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850905079 Withdrawn EP0199753A1 (fr) 1984-10-19 1985-10-16 Anticorps monoclonaux et leur utilisation

Country Status (3)

Country Link
EP (1) EP0199753A1 (fr)
GB (1) GB8426465D0 (fr)
WO (1) WO1986002354A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878610B (en) * 1986-11-20 1989-06-28 Minnesota Mining & Mfg Method for the evaluation of oral microbes
US5281416A (en) * 1986-12-23 1994-01-25 Royal Melbourne Institute Of Technology Limited Swine dysentery vaccine
CA1304289C (fr) * 1986-12-23 1992-06-30 Peter John Coloe Epreuve diagnostique de la dysenterie porcine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461829A (en) * 1981-09-14 1984-07-24 Miles Laboratories, Inc. Homogeneous specific binding assay element and lyophilization production method
US4514498A (en) * 1982-05-26 1985-04-30 The Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Treponema

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8602354A1 *

Also Published As

Publication number Publication date
GB8426465D0 (en) 1984-11-28
WO1986002354A1 (fr) 1986-04-24

Similar Documents

Publication Publication Date Title
WO1986002364A1 (fr) Anticorps monoclonaux et leur utilisation
EP0203088A1 (fr) Anticorps monoclonaux et leur utilisation
WO1986002359A1 (fr) Anticorps monoclonaux et leur utilisation
WO1986002355A1 (fr) Anticorps monoclonaux et leur utilisation
EP0198866A1 (fr) Anticorps monoclonaux et leur utilisation
EP0229146A1 (fr) Anticorps monoclonaux et leur utilisation
EP0199753A1 (fr) Anticorps monoclonaux et leur utilisation
EP0201520A1 (fr) Anticorps monoclonaux et leur utilisation
WO1986002365A1 (fr) Anticorps monoclonaux et leur utilisation
EP0192728A1 (fr) Anticorps monoclonaux et leur utilisation
EP0201519A1 (fr) Anticorps monoclonaux et leur utilisation
EP0204798A1 (fr) Anticorps monoclonaux et leur utilisation
WO1987006616A1 (fr) Anticorps monoclonaux et leur utilisation
EP0199754A1 (fr) Anticorps monoclonaux et leur utilisation
WO1986002361A1 (fr) Anticorps monoclonaux et leur utilisation
WO1987006469A1 (fr) Anticorps monoclonaux et leur utilisation
WO1986002357A1 (fr) Anticorps monoclonaux et leur utilisation
EP0189451A1 (fr) Anticorps monoclonaux et leur utilisation
EP0187801A1 (fr) Anticorps monoclonaux et leur utilisation
EP0187802A1 (fr) Anticorps monoclonaux et leur utilisation
EP0265478A1 (fr) Anticorps monoclonaux et leur utilisation
EP0188491A1 (fr) Anticorps monoclonaux et leur utilisation
EP0189450A1 (fr) Anticorps monoclonaux et leur utilisation
EP0190185A1 (fr) Anticorps monoclonaux et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860923

RIN1 Information on inventor provided before grant (corrected)

Inventor name: COPLEY, CLIVE, GRAHAM

Inventor name: NOYES, ALICE, MARGARET

Inventor name: COX, PETER, JOHN

Inventor name: WIDDOWS, DANNY

Inventor name: WRIGHT, BRUCE, WILLIAM